These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12270254)

  • 1. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation.
    Dunbar C; Scheuch G; Sommerer K; DeLong M; Verma A; Batycky R
    Int J Pharm; 2002 Oct; 245(1-2):179-89. PubMed ID: 12270254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates.
    DeLong M; Wright J; Dawson M; Meyer T; Sommerer K; Dunbar C
    J Aerosol Med; 2005; 18(4):452-9. PubMed ID: 16379620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
    Lim JG; Shah B; Rohatagi S; Bell A
    Am J Ther; 2006; 13(1):32-42. PubMed ID: 16428920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
    Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
    Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
    Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
    Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder.
    Duddu SP; Sisk SA; Walter YH; Tarara TE; Trimble KR; Clark AR; Eldon MA; Elton RC; Pickford M; Hirst PH; Newman SP; Weers JG
    Pharm Res; 2002 May; 19(5):689-95. PubMed ID: 12069174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.
    Newman SP; Sutton DJ; Segarra R; Lamarca R; de Miquel G
    Respiration; 2009; 78(3):322-8. PubMed ID: 19451700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique.
    Warren S; Taylor G; Smith J; Buck H; Parry-Billings M
    J Aerosol Med; 2002; 15(1):15-25. PubMed ID: 12006142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers.
    Glover W; Chan HK; Eberl S; Daviskas E; Verschuer J
    Int J Pharm; 2008 Feb; 349(1-2):314-22. PubMed ID: 17904774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    Usmani OS; Biddiscombe MF; Barnes PJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1497-504. PubMed ID: 16192448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose.
    Ung KT; Rao N; Weers JG; Huang D; Chan HK
    Int J Pharm; 2016 Sep; 511(2):1070-9. PubMed ID: 27480399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
    Van Holsbeke C; De Backer J; Vos W; Marshall J
    Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
    Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
    Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data.
    Meyer T; Brand P; Ehlich H; Köbrich R; Meyer G; Riedinger F; Sommerer K; Weuthen T; Scheuch G
    J Aerosol Med; 2004; 17(1):43-9. PubMed ID: 15120012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung deposition and respirable mass during wet nebulization.
    Sangwan S; Condos R; Smaldone GC
    J Aerosol Med; 2003; 16(4):379-86. PubMed ID: 14977428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.
    Wang YB; Watts AB; Peters JI; Liu S; Batra A; Williams RO
    AAPS PharmSciTech; 2014 Aug; 15(4):981-93. PubMed ID: 24824172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort.
    Pitcairn GR; Lankinen T; Seppälä OP; Newman SP
    J Aerosol Med; 2000; 13(2):97-104. PubMed ID: 11010599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.